Poor compliance with adjuvant chemotherapy use associated with poorer survival in patients with rectal cancer: An NCDB analysis.

摘要: BACKGROUND National Comprehensive Cancer Network treatment guidelines for patients with locally advanced rectal cancer include neoadjuvant chemoradiation followed by total mesorectal excision and adjuvant chemotherapy. The objective of the current study was to examine rate chemotherapy associated survival in stage II/III cancer. METHODS The 2006 2011 National Data Base queried AJCC clinical who underwent surgical resection. A mixed effects multivariable logistic regression identified factors receipt Cox proportional hazards model used estimate adjusted effect receiving therapy on 5-year overall (OS). RESULTS A 14,742 were included; 68% cohort did not receive When controlled disease, aged >70 years, had a higher comorbidity score, pathologic complete response lower odds therapy. There 22-fold difference risk-adjusted use among hospitals (3.1%-67.7%). Adjuvant increased OS when patient factors, (hazard ratio, 0.65; 95% confidence interval, 0.59-0.71). greatest benefit noted achieved 0.40; 0.23-0.67). CONCLUSIONS There is poor compliance after surgery. appears be independently improved regardless response, factors. observed responders. Age comorbidities found significantly nonreceipt Improved rehabilitation physical conditioning may improve 2016. © 2016 American Society.